138 related articles for article (PubMed ID: 25581115)
1. Attorneys aim to reform "compassionate use": groups say the regulatory system lags behind scientific advances.
Printz C
Cancer; 2015 Jan; 121(2):163-4. PubMed ID: 25581115
[No Abstract] [Full Text] [Related]
2. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
3. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
4. Expanded access rules pose quandary for drug developers.
Mack GS
Nat Biotechnol; 2009 Oct; 27(10):871-2. PubMed ID: 19816423
[No Abstract] [Full Text] [Related]
5. "Right to Try" laws.
Begg CB; Kim K; Neaton JD
Clin Trials; 2014 Oct; 11(5):519-20. PubMed ID: 25190026
[No Abstract] [Full Text] [Related]
6. Fairer way to distribute last-ditch drugs gets real-world trial.
Reardon S
Nature; 2016 Jun; 534(7606):160-1. PubMed ID: 27279187
[No Abstract] [Full Text] [Related]
7. The Right to Try: An Overview of Efforts to Obtain Expedited Access to Unapproved Treatment for the Terminally Ill.
Tsakopoulos A; Han J; Nodler H; Russo V
Food Drug Law J; 2015; 70(4):617-41. PubMed ID: 26827394
[No Abstract] [Full Text] [Related]
8. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
Bateman-House A; Robertson CT
JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
[No Abstract] [Full Text] [Related]
9. [Off-label use of drugs--the legal framework].
Koyuncu A
Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
[No Abstract] [Full Text] [Related]
10. Food and Drug Administration, partner in drug development.
Yates JW
CA Cancer J Clin; 2006; 56(6):321-2. PubMed ID: 17135690
[No Abstract] [Full Text] [Related]
11. US lawyers investigate trial that secured license for AstraZeneca's antiplatelet drug.
Cohen D
BMJ; 2013 Nov; 347():f6727. PubMed ID: 24212110
[No Abstract] [Full Text] [Related]
12. New drug law to speed scientific review.
Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
[TBL] [Abstract][Full Text] [Related]
13. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
14. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
15. Right-to-try laws: hope, hype, and unintended consequences.
Bateman-House A; Kimberly L; Redman B; Dubler N; Caplan A
Ann Intern Med; 2015 Nov; 163(10):796-7. PubMed ID: 26413841
[No Abstract] [Full Text] [Related]
16. The FDA and "privatization"--the drug approval process.
Rutherford EM
Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
[No Abstract] [Full Text] [Related]
17. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
18. More support for clinical trials in children.
Nature; 2016 Jul; 535(7613):465-6. PubMed ID: 27466087
[No Abstract] [Full Text] [Related]
19. The Ethical Challenges of Compassionate Use.
Caplan AL; Ray A
JAMA; 2016 Mar; 315(10):979-80. PubMed ID: 26868205
[No Abstract] [Full Text] [Related]
20. Regulatory watch: impact of PDUFA on regulatory decision-making.
Hay M
Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
